Overview

A Multicenter Trial of Rofecoxib and Naproxen in Alzheimer's Disease (NSAID Study)

Status:
Completed
Trial end date:
2001-12-01
Target enrollment:
Participant gender:
Summary
The primary specific aim of this clinical trial is to determine whether treatment with rofecoxib or naproxen for one year will slow the rate of decline of cognitive function in patients with Alzheimer's disease (AD) as measured by ADAScog.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
National Institute on Aging (NIA)
Collaborator:
Alzheimer's Disease Cooperative Study (ADCS)
Treatments:
Naproxen
Rofecoxib